Tags

Type your tag names separated by a space and hit enter

Pleiotropic effects of statins: do they matter?
Curr Opin Lipidol. 2001 08; 12(4):391-4.CO

Abstract

Treatment with the 3-hydroxy-3-methylglutaryl coenyzme A reductase inhibitors (or statins) reduces the risk for cardiovascular events across a broad spectrum of patient profiles, as evidenced by both primary prevention and secondary prevention trials. Improved survival by way of reduced deaths from coronary heart disease was also reported with these agents, which are primarily indicated for substantial reduction in LDL-cholesterol levels. However, the statins are extremely complex drugs and exhibit a wide variety of vascular effects that may or may not be dependent on their lipid-modifying properties. These so-called pleiotropic effects include alterations of endothelial function, inflammation, coagulation, and plaque stability. The relative contribution of the nonlipid effects of statin therapy to the well-documented clinical benefits is currently under intense investigation.

Authors+Show Affiliations

Weill Medical College of Cornell University, New York, New York 10021, USA. amg_editorial@med.cornell.eduNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11507323

Citation

Gotto, A M., and J A. Farmer. "Pleiotropic Effects of Statins: Do They Matter?" Current Opinion in Lipidology, vol. 12, no. 4, 2001, pp. 391-4.
Gotto AM, Farmer JA. Pleiotropic effects of statins: do they matter? Curr Opin Lipidol. 2001;12(4):391-4.
Gotto, A. M., & Farmer, J. A. (2001). Pleiotropic effects of statins: do they matter? Current Opinion in Lipidology, 12(4), 391-4.
Gotto AM, Farmer JA. Pleiotropic Effects of Statins: Do They Matter. Curr Opin Lipidol. 2001;12(4):391-4. PubMed PMID: 11507323.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pleiotropic effects of statins: do they matter? AU - Gotto,A M,Jr AU - Farmer,J A, PY - 2001/8/17/pubmed PY - 2001/9/28/medline PY - 2001/8/17/entrez SP - 391 EP - 4 JF - Current opinion in lipidology JO - Curr. Opin. Lipidol. VL - 12 IS - 4 N2 - Treatment with the 3-hydroxy-3-methylglutaryl coenyzme A reductase inhibitors (or statins) reduces the risk for cardiovascular events across a broad spectrum of patient profiles, as evidenced by both primary prevention and secondary prevention trials. Improved survival by way of reduced deaths from coronary heart disease was also reported with these agents, which are primarily indicated for substantial reduction in LDL-cholesterol levels. However, the statins are extremely complex drugs and exhibit a wide variety of vascular effects that may or may not be dependent on their lipid-modifying properties. These so-called pleiotropic effects include alterations of endothelial function, inflammation, coagulation, and plaque stability. The relative contribution of the nonlipid effects of statin therapy to the well-documented clinical benefits is currently under intense investigation. SN - 0957-9672 UR - https://www.unboundmedicine.com/medline/citation/11507323/Pleiotropic_effects_of_statins:_do_they_matter L2 - http://dx.doi.org/10.1097/00041433-200108000-00004 DB - PRIME DP - Unbound Medicine ER -